Pacific Biosciences of California (PACB : NASDAQ)
Common Stock
$2.37
USD
+0.54 (29.51%)
Last updated: 2026-09-30
Follow PACB
PACB
Pacific Biosciences of California
WealthAwesomePerformance
1 Day
+29.51%
1 Week
+68.09%
1 Month
+74.26%
YTD
+76.87%
Key Statistics
Market Cap
$736.67M
52W High
$2.73
52W Low
$1.07
P/E Ratio
-
50 Day MA
$1.36
200 Day MA
$1.57
Beta
2.31
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/30/2026 | $1.84 | $2.46 | $1.84 | $2.37 | $2.37 | 80,386,307 |
| 9/29/2026 | $1.68 | $1.85 | $1.63 | $1.83 | $1.83 | 17,398,390 |
| 9/28/2026 | $1.60 | $1.80 | $1.59 | $1.71 | $1.71 | 21,281,906 |
| 9/25/2026 | $1.57 | $1.63 | $1.52 | $1.62 | $1.62 | 11,358,900 |
| 9/24/2026 | $1.40 | $1.58 | $1.38 | $1.58 | $1.58 | 10,843,470 |
| 9/23/2026 | $1.45 | $1.47 | $1.39 | $1.41 | $1.41 | 5,257,416 |
| 9/22/2026 | $1.38 | $1.48 | $1.36 | $1.47 | $1.47 | 7,837,948 |
| 9/21/2026 | $1.37 | $1.40 | $1.34 | $1.36 | $1.36 | 6,126,601 |
| 9/18/2026 | $1.38 | $1.40 | $1.34 | $1.37 | $1.37 | 4,911,000 |
| 9/17/2026 | $1.37 | $1.43 | $1.36 | $1.38 | $1.38 | 6,227,328 |
Analyst Price Targets
Based on 14 analysts covering PACB · as of Sep 17, 2026
Wall Street analysts forecast PACB stock price to fall 9.0% over the next 12 months.
Consensus
Buy3.79 / 5.00
Avg. Target
US$2.16
-9.0% Upside
Current Price
US$2.37
Last close
Analyst Breakdown (14 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on PACB's historical volatility
30-Day Vol
115.7%
Annualized
90-Day Vol
95.9%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$2.83
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$2.52 | US$1.69 – US$3.75 |
| 60 trading days | US$2.67 | US$1.52 – US$4.70 |
| 90 trading days | US$2.83 | US$1.42 – US$5.66 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Pacific Biosciences of California
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Financials
- Revenue (TTM)
- $159.27M
- EBITDA
- $199.18M
- Profit Margin
- -82.49%
- ROE (TTM)
- -929.32%
- EPS (Diluted)
- -0.42
- Book Value
- -0.11
Classification
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About PACB.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| NIVF | NewGenIvf Group Limited Class A Ordinary Shares | $0.17 | +133.33% |
| EURKR | Eureka Acquisition Corp Right | $0.41 | +62.14% |
| CMCT | Creative Media & Community Trust Corporation | $2.93 | +52.60% |
| TNON | Tenon Medical Inc | $4.09 | +49.82% |
| AHG | Akso Health Group ADR | $0.90 | +30.25% |
| GRAN | Grande Group Limited Class A Ordinary Shares | $1.09 | +30.13% |
| AIXC | AIxCrypto Holdings, Inc. | $1.31 | +29.70% |
| FNGR | FingerMotion Inc | $0.18 | +28.25% |